LAWRENCE H FONG

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Interplay between CD8α+ dendritic cells and monocytes in response to Listeria monocytogenes infection attenuates T cell responses
    Dilnawaz Kapadia
    Division of Hematology Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 6:e19376. 2011
  2. pmc Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation
    Lawrence Fong
    Department of Pathology, Stanford University School of Medicine, Stanford, California 94304, USA
    J Virol 76:11033-41. 2002
  3. doi request reprint Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment
    Lawrence Fong
    Department of Medicine, Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94143 0511, USA
    J Clin Oncol 26:5275-83. 2008
  4. pmc CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
    Brian Kavanagh
    Department of Microbiology and Immunology, Division of Hematology Oncology, University of California, San Francisco, CA 94143, USA
    Blood 112:1175-83. 2008
  5. pmc Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy
    Charles J Ryan
    Urologic Oncology Program, University of California, San Francisco, San Francisco, CA 94115, USA
    J Clin Oncol 28:1481-8. 2010
  6. doi request reprint Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF
    Lawrence Fong
    Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Res 69:609-15. 2009
  7. pmc SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
    Marcella Fassò
    Departments of Urology and Medicine, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 105:3509-14. 2008
  8. ncbi request reprint Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome
    Charles J Ryan
    Urologic Oncology Program, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94115, USA
    J Urol 178:2372-6; discussion 2377. 2007
  9. ncbi request reprint Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides
    Brian Kavanagh
    Department of Medicine, Division of Hematology Oncology, University of California, San Francisco, CA 94143, USA
    J Immunother 30:762-72. 2007
  10. ncbi request reprint Immunotherapy for prostate cancer
    Lawrence Fong
    University of California, San Francisco, San Francisco, CA 94143 0511, USA
    Curr Oncol Rep 9:226-33. 2007

Research Grants

  1. Dendritics Cell Immunotherapy for Colorectal Cancer
    Lawrence Fong; Fiscal Year: 2004
  2. Dendritics Cell Immunotherapy for Colorectal Cancer
    Lawrence Fong; Fiscal Year: 2005
  3. Dendritics Cell Immunotherapy for Colorectal Cancer
    Lawrence Fong; Fiscal Year: 2006
  4. Dendritics Cell Immunotherapy for Colorectal Cancer
    Lawrence Fong; Fiscal Year: 2007
  5. Prostate Cancer Immunotherapy
    Lawrence Fong; Fiscal Year: 2009
  6. Prostate Cancer Immunotherapy
    Lawrence Fong; Fiscal Year: 2010

Collaborators

Detail Information

Publications22

  1. pmc Interplay between CD8α+ dendritic cells and monocytes in response to Listeria monocytogenes infection attenuates T cell responses
    Dilnawaz Kapadia
    Division of Hematology Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 6:e19376. 2011
    ..Thus these monocytes enhance IL-12 production to Lm infection, but concurrently abrogate DC-mediated T cell priming...
  2. pmc Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation
    Lawrence Fong
    Department of Pathology, Stanford University School of Medicine, Stanford, California 94304, USA
    J Virol 76:11033-41. 2002
    ..IPC also induce naïve CD4 T cells to proliferate and would therefore preferentially infect these cells. These results indicate that IPC may play an important role in the dissemination of HIV...
  3. doi request reprint Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment
    Lawrence Fong
    Department of Medicine, Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94143 0511, USA
    J Clin Oncol 26:5275-83. 2008
    ..Antibodies (ipilimumab and tremelimumab) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), an inhibitory molecule on T cells, represent the vanguard of these new drugs...
  4. pmc CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
    Brian Kavanagh
    Department of Microbiology and Immunology, Division of Hematology Oncology, University of California, San Francisco, CA 94143, USA
    Blood 112:1175-83. 2008
    ..Our results also suggest that CTLA4 may inhibit Treg proliferation similar to its role on effector T cells. This study is registered at http://www.clinicaltrials.gov/ct2/show/NCT00064129, registry number NCT00064129...
  5. pmc Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy
    Charles J Ryan
    Urologic Oncology Program, University of California, San Francisco, San Francisco, CA 94115, USA
    J Clin Oncol 28:1481-8. 2010
    ..This phase I dose-escalation study of abiraterone acetate evaluated safety, pharmacokinetics, and effects on steroidogenesis and prostate-specific antigen (PSA) levels in men with CPRC with or without prior ketoconazole therapy...
  6. doi request reprint Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF
    Lawrence Fong
    Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Res 69:609-15. 2009
    ....
  7. pmc SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
    Marcella Fassò
    Departments of Urology and Medicine, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 105:3509-14. 2008
    ..Our findings demonstrate that our in vivo CTLA-4 blockade-based T cell expression cloning can identify immunogenic cancer antigens with potential relevance for human immunotherapy...
  8. ncbi request reprint Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome
    Charles J Ryan
    Urologic Oncology Program, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94115, USA
    J Urol 178:2372-6; discussion 2377. 2007
    ..The efficacy of ketoconazole plus the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor was prospectively evaluated in patients with castration resistant prostate cancer with and without metastases...
  9. ncbi request reprint Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides
    Brian Kavanagh
    Department of Medicine, Division of Hematology Oncology, University of California, San Francisco, CA 94143, USA
    J Immunother 30:762-72. 2007
    ....
  10. ncbi request reprint Immunotherapy for prostate cancer
    Lawrence Fong
    University of California, San Francisco, San Francisco, CA 94143 0511, USA
    Curr Oncol Rep 9:226-33. 2007
    ..Emerging trials have demonstrated that immunotherapy may generate not only immune responses in patients but also clinical responses. Future studies will be directed at capitalizing on these findings...
  11. ncbi request reprint A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Clin Cancer Res 13:1810-5. 2007
    ....
  12. ncbi request reprint Immunotherapy for prostate cancer
    Lawrence Fong
    Department of Medicine, University of California, San Francisco, CA 94143, USA
    Semin Oncol 30:649-58. 2003
    ..Immunotherapy trials have already demonstrated evidence of not only immunogenicity, but also clinical efficacy, and future studies will be directed at capitalizing on these findings...
  13. ncbi request reprint Immunotherapy for prostate cancer
    Lawrence Fong
    University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Curr Urol Rep 7:239-46. 2006
    ..Emerging trials have demonstrated that immunotherapy may not only generate immune responses in patients, but also clinical responses. Future studies will be directed at capitalizing on these findings...
  14. pmc HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase
    Brian M Olson
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Cancer Immunol Immunother 59:943-53. 2010
    ..In addition, we propose that the epitopes identified here could be used to monitor immune responses in HLA-A2+ patients receiving vaccines targeting PAP to identify potentially therapeutic immune responses...
  15. ncbi request reprint A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy
    Amy M Lin
    University of California San Francisco, San Francisco, CA 94115, USA
    BJU Int 98:763-9. 2006
    ..East Hanover, NJ, USA), as measured by prostate-specific antigen (PSA) kinetics in men with biochemical relapse of prostate cancer after definitive local therapy...
  16. ncbi request reprint Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients
    Edgar G Engleman
    Department of Pathology, Stanford University School of Medicine, CA 94305, USA
    Clin Immunol 106:10-5. 2003
  17. ncbi request reprint Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor
    Brian I Rini
    University of California San Francisco Comprehensive Cancer Center, San Francisco, California, USA
    J Urol 175:2087-91. 2006
    ..We describe the clinical and immunological characteristics of patients with biochemically relapsed prostate cancer who achieved long-term disease control with GM-CSF (Leukine)...
  18. ncbi request reprint A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer
    Eric J Small
    University of California, Comprehensive Cancer Center San Francisco, San Francisco, CA 94143, USA
    Mol Ther 14:107-17. 2006
    ..No partial or complete prostate-specific antigen (PSA) responses were observed; however, 5 patients had a decrease in serum PSA of 25% to 49% following a single treatment, including 3 of 8 patients at the highest dose levels...
  19. ncbi request reprint Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen
    Yafei Hou
    Division of Hematology Oncology, Department of Medicine, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    J Immunol 180:1526-34. 2008
    ..These results demonstrate that priming with this CEA-derived altered peptide ligand can induce distinct carcinoembryonic Ag-reactive T cells with different functional capacities...
  20. pmc An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans
    Yafei Hou
    Division of Hematology Oncology, Department of Medicine, University of California, San Francisco, California 94143, USA
    J Clin Invest 119:2031-41. 2009
    ..Moreover, SVS2 and semenogelin are among the relevant autoantigens in mice and humans, respectively...
  21. ncbi request reprint In vivo manipulation of dendritic cells to induce therapeutic immunity
    Miriam Merad
    Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
    Blood 99:1676-82. 2002
    ..Natural killer cells also contributed to tumor protection. These results show that dendritic cells can be loaded with antigen and activated, in situ, and provide the basis for dendritic cell- targeted clinical strategies...
  22. pmc A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies
    Amy J Chien
    Department of Medicine, University of California San Francisco, San Francisco, California 94143 0875, USA
    Clin Cancer Res 15:5569-75. 2009
    ..This study investigates the clinical relevance of this approach...

Research Grants7

  1. Dendritics Cell Immunotherapy for Colorectal Cancer
    Lawrence Fong; Fiscal Year: 2004
    ..The proposed studies will provide the foundation for a more potent DC targeted cancer immunotherapy for the future. ..
  2. Dendritics Cell Immunotherapy for Colorectal Cancer
    Lawrence Fong; Fiscal Year: 2005
    ..The proposed studies will provide the foundation for a more potent DC targeted cancer immunotherapy for the future. ..
  3. Dendritics Cell Immunotherapy for Colorectal Cancer
    Lawrence Fong; Fiscal Year: 2006
    ..The proposed studies will provide the foundation for a more potent DC targeted cancer immunotherapy for the future. ..
  4. Dendritics Cell Immunotherapy for Colorectal Cancer
    Lawrence Fong; Fiscal Year: 2007
    ..The proposed studies will provide the foundation for a more potent DC targeted cancer immunotherapy for the future. ..
  5. Prostate Cancer Immunotherapy
    Lawrence Fong; Fiscal Year: 2009
    ..Defining the target proteins against which this immune response is induced may lead to improved treatments for prostate cancer. ..
  6. Prostate Cancer Immunotherapy
    Lawrence Fong; Fiscal Year: 2010
    ..Defining the target proteins against which this immune response is induced may lead to improved treatments for prostate cancer. ..